Merck & Co., Inc.
Every calculator, already run for MRK
Open the full toolkit →You have the numbers on MRK. Get the argument.
A written report on which of these readings actually decide the outcome for Merck & Co., Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
28 analysts covering MRKAnalyst Price Target Disagreement for Merck & Co., Inc.
Wall Street's bull case implies +27% from the current price; the bear case implies -29%. A 55% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for MRK
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Merck & Co., Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent…
MRK — frequently asked
Is MRK a buy right now?
Wall Street's consensus rating on Merck & Co., Inc. is Buy across 28 analysts, with a mean price target of $152.96 (+4% vs. the current $146.87). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is MRK overvalued?
MRK trades at 117.5x trailing earnings, against a DCF fair value of $239 per share. The current price implies 0% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is MRK's next earnings date?
Merck & Co., Inc. is next scheduled to report earnings around Oct 29, 2026. A full MRK research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Merck & Co., Inc.?
Analysts covering Merck & Co., Inc. (MRK) range from a bear-case target of $105.00 to a bull-case high of $186.00, with a mean consensus target of $152.96 across 26 analysts. The spread of $81.00 (55% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Merck & Co., Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Merck & Co., Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full MRK research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Merck & Co., Inc., in minutes. 3 free reports included with every account — no credit card required.